Which cisplatin regimen is preferred for concurrent chemoradiation for definitive treatment of muscle invasive bladder cancer?
Weekly (20 mg/m2 D1, D2) and q 3 wks (70 mg/m2 x 3c or 100 mg/m2 x 3c) regimens have all been listed as acceptable. For reference, RTOG 97–06, RTOG 88–02, RTOG 89–03. Please provide rationale, whether simply opinion or evidence based, and provide practical guidance points, if any (e.g. neutropenia or severe adverse effect concerns).
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Washington School of Medicine
Answered on
I tend to use 35 - 40 mg/m2 once weekly, ideally on Mondays (I think that SN1806 is using 35 mg/m2 weekly).
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · AdventHealth Cancer Institute
Answered on
There is not a single optimal chemotherapy regimen that has been determined based on a large randomized trial evaluating chemoradiation for muscle-invasive bladder cancer. Indeed, the only chemotherapy regimen proven to improve locoregional outcomes (but not survival) in a phase III trial is 5FU + M...
Join for free or sign in to see the full answer